

## **Avon & Wiltshire Mental Health Partnership NHS Trust (AWP), Adult ADHD Service and Takeda UK Limited**

### Joint Working Project Summary

The AWP Adult ADHD Service and Takeda UK Limited, are embarking on a joint working venture to develop an Adult ADHD Outcome Assessments Mobile App. The parties have agreed that the Project should be undertaken in accordance with the principles and guidance relating to joint working between the NHS and the pharmaceutical industry. The Project's primary aim is to design an App to capture health outcomes for patients under the care of the AWP Adult ADHD Service. AWP are contracting with Leicestershire Partnership NHS Trust Health Informatics department to develop and host the app. The anticipated benefits to the Adult ADHD Outcome Assessment Mobile App are as follows:

- Improved Service User Satisfaction post implementation
- Improved decision making in treatment post implementation
- Benefits to the NHS post implementation in terms of cost savings, efficacy and efficiency
- Improved Capturing of Patient Health Outcomes post implementation
- AWP Adult ADHD Service able to prove interventions are effective on patient group as a whole
- Education for GPs, CCGs, other ADHD Services and psychiatric services

Due to COVID-19 the implementation of the App has been delayed and the original implementation plan has needed to be altered. Originally patients were to complete the assessment questionnaires in the clinic during the appointment. Due to the COVID-19 related restructuring of the Bristol Adult ADHD Service this is no longer possible so the App has been reconfigured to work on patient devices and via secure NHS Digital two factor authentication sign in.

The original financial commitments of both parties, AWP and Takeda UK Limited are similar and significant. AWP were originally contributing £52,880 and Takeda UK Limited were contributing £60,800, meaning that AWP were providing 47% of the funding and Takeda UK Limited were contributing 53%.

With the changes to the app requiring additional work and time commitment these costs have now risen AWP are now contributing at total of £64,224 and Takeda UK Limited are contributing a total of £74,510, meaning that AWP are providing 47% of the funding and Takeda UK Limited are contributing 53%. The original project commenced in September 2018 and was expected continue for a period of at least 19 months. This has been extended [until December 2021] due to the impact of COVID-19. The Project is expected to bring benefits to the patient, AWP and Takeda UK Limited.

The objective of this Joint Working Project is to better monitor and demonstrate the clinical effectiveness of treatment. A further goal is to increase the capacity of the ADHD Service without the need for additional human resources.

It is designed to support:

- Improved Patient outcomes and the recording of treatment outcomes
- Increased clinical capacity within the team
- More effective assessment, treatment and interventions

Item Code: C-ANPROM/GB/NBU/0027

Date of Preparation: January 2023

- Training for relevant medical and non-medical practitioners, especially on the use of appropriate objective tests for ADHD including rating scales and diagnostic tools.
- Ascertaining the effectiveness of interventions
- Improved recognition of co-morbid conditions
- Improved clinician satisfaction
- Collation of practice based evidence

**It is anticipated that a report on the outcomes from this joint working will be published during 2021/2.**

In connection with a proposed legal reorganisation, on 1 April 2021 Takeda UK Limited will assume all rights and obligations under this joint working project in place of Shire Pharmaceuticals Limited. This follows the acquisition of Shire PLC and its subsidiaries, including Shire Pharmaceuticals Limited, by Takeda Pharmaceutical Company Limited on 8 January 2019. Takeda UK Limited and Shire Pharmaceuticals Limited are both members of the Takeda group of companies.

**For further information please contact:**

Takeda UK – Donna Flood, Service Development Manager, 07824 104167 [donna.flood@takeda.com](mailto:donna.flood@takeda.com)

AWP – Dr Dietmar Hank, Consultant Psychiatrist, 01275796262, [dietmarhank@nhs.net](mailto:dietmarhank@nhs.net)

Leicestershire HIS – Harvi Singh Kaley, Application Software Development Manager, 0116 295 2342, [harvinder.Kaley@leics-his.nhs.uk](mailto:harvinder.Kaley@leics-his.nhs.uk)